Previously dba NaPro BioTherapeutics, Inc.Tapestry Pharmaceuticals, Inc. had been organized primarily around three elements: production and sale of Paclitaxel, an approved cancer drug; the development of targeted oncology products, and the development of novel genomic technologies, primarily in the area of gene editing for applications in human therapeutics, diagnostics, agribiotechnology and pharmacogenomics. Developing proprietary therapies for the treatment of cancer, the firm also was structured to evaluate new therapeutic agents and related technologies that involve the examination of individual molecules, classes of compounds, and platform technologies. The Company's commercialized product had been Paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus, trees. The Company also worked on several types of compounds that have promising activity as anti-cancer agents. NaPro BioTherapeutics had been engaged in evaluating the in-licensing or purchase of potential new products and/or technologies, whether or not those products or technologies are derived from natural products. In December 2003, the Company sold its worldwide generic injectable Paclitaxel business to Mayne Pharma. Duirng the financial crises of 2008 the firm was delisted fromNASDAQ and filed for bankrupcy
